



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

#21

Food and Drug Administration
Rockville MD 20857

NOV 4 1991

Re: Altace
Docket No. 91E-0136

Charles E. Van Horn, Esq.
Patent Policy and Projects Administrator
Office of the Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Crystal Park Building 2, Suite 919
Washington, DC 20231

Dear Mr. Van Horn:

This is in regard to the patent term extension application for U.S. Patent No. 4,587,258 filed by Hoechst-Roussel Pharmaceuticals, Inc., under 35 U.S.C. 156. The patent claims the human drug product Altace, NDA 19-901.

In the May 10, 1991, issue of the Federal Register, the Food and Drug Administration published its determination of the product's regulatory review period, as required under 35 U.S.C. 156(d)(2)(A). The notice provided that on or before November 6, 1991, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to the notice has expired, and FDA has received no such petition. FDA, therefore, considers Altace's regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Ronald L. Wilson
Director
Health Assessment Policy Staff
Office of Health Affairs

cc: Tatsuya Ikeda
Patent Department
Hoechst Celanese Corporation
P.O. Box 2500
Route # 202-206 North
Somerville, New Jersey 08876-1258

OFFICE OF THE ASSISTANT
COMMISSIONER FOR PATENTS

NOV - 7 1991

RECEIVED